<DOC>
	<DOC>NCT00913120</DOC>
	<brief_summary>The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.</brief_summary>
	<brief_title>Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<criteria>Subjects is scheduled for elective primary total hip replacement surgery Written informed consent obtained before screening Subject has history of deep vein thrombosis and/or pulmonary embolism Subject has a hemorrhagic disorder and/or coagulation disorder Subject has had clinically important bleeding occurred within 90 days prior to the screening visit Subject has an acute bacterial endocarditis, retinopathy, hypertension, or thrombocytopenia Subject is receiving anticoagulants/antiplatelet agents</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>YM150</keyword>
	<keyword>FXa inhibitor</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Anticoagulant</keyword>
	<keyword>Venous thromboembolism</keyword>
	<keyword>Arthroplasty, replacement, hip</keyword>
</DOC>